SEC Tracker
Get the app

TriSalus Life Sciences TLSI

TriSalus Life Sciences reported Q3 2026 revenue of $12.9 million

TriSalus Life Sciences (TLSI) filed an 8-K with the SEC on Nov 10, 2026, 8:07 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Revenue increased 11.3% year-over-year
  2. Revised 2026 revenue guidance to $46 million to $48 million
  3. Gross margins improved to 86.2%
  4. Net loss narrowed to $8.9 million from $41.3 million

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when TriSalus Life Sciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.